Cyteir Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cyteir Therapeutics Inc (CYT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cyteir Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,545M vs 5,520M combined for tracked competitors (21.9% combined share).
- Peer differentiation: Revenue per employee of $15.77M compares with $0.62M for the peer group (25.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Cyteir Therapeutics Inc vs. its Competitors, Q3 2023
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cyteir Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cyteir Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cyteir Therapeutics Inc's competitor groups requires a Commercial License.
Cyteir Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cyteir Therapeutics Inc | - | - | - | No |
| Competitors combined (61) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CYT Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Adlai Nortye Ltd | 282.9% | Outperformed |
| 2 | Erasca Inc | 282.9% | Outperformed |
| 3 | Iovance Biotherapeutics inc | 282.9% | Outperformed |
| 4 | Nurix Therapeutics Inc | 282.9% | Outperformed |
| 5 | Enliven Therapeutics Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cyteir Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Cyteir Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cyteir Therapeutics Inc | 108.81 | 1,545.00 |
| Madrigal Pharmaceuticals Inc | 15,069.27 | 1,283.94 |
| Hutchmed china Limited | 12,333.95 | 548.51 |
| Nuvalent Inc | 9,751.98 | 4.23 |
| Immunogen inc | 8,981.44 | 287.61 |
| Blueprint Medicines Corporation | 8,615.12 | 562.12 |
| SUBTOTAL | 111,580.66 | 7,144.00 |
Sign in to see all competitors of Cyteir Therapeutics Inc .
Sources: Cyteir Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cyteir Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cyteir Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Madrigal Pharmaceuticals Inc | Reportable 100.00 % |
| Hutchmed china Limited | Other Ventures segment 47.94 % |
| Blueprint Medicines Corporation | Single Reportable Segment 100.00 % |
| Rhythm Pharmaceuticals Inc | Single Reportable 100.00 % |
| Iovance Biotherapeutics inc | Single reportable segment 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Cyteir Therapeutics Inc .
Cyteir Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cyteir Therapeutics Inc | 109 | 15,765,306 | -338,929 |
| Madrigal Pharmaceuticals Inc | 15,069 | 1,403,213 | -355,295 |
| Hutchmed china Limited | 12,334 | 703,221 | 586,836 |
| Nuvalent Inc | 9,752 | 18,566 | -1,974,009 |
| Immunogen inc | 8,981 | 831,254 | -212,491 |
| Blueprint Medicines Corporation | 8,615 | 965,844 | -267,576 |
| PEERS TOTAL | 111,472 | 621,627 | -471,194 |
Sign in to see all peers for Cyteir Therapeutics Inc .
Cyteir Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Hutchmed china Limited | CN 74.28 % |
| Iovance Biotherapeutics inc | US 98.66 % |
| Xoma Royalty Corporation | CH 54.36 % |
| Adc Therapeutics Sa | United States 96.08 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Cyteir Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 0.8x | 4.5x | -3.7x |
| Return on Equity | -24.88 % | industry aggregate | -36.34 % |
| Return on Invested Capital | -14.30 % | -2.95 % (avg) | -11.35 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cyteir Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2014 | 2021 | 2022 |
|---|---|---|---|
| Revenue Growth | 29.95 % | - | - |
| Operating Margin | 11.64 % | - | - |
| Return on Invested Capital | 6.34 % | -47.93 % | -14.99 % |
| P/E | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cyteir Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 36.3 points below the industry aggregate.
Opportunities
- A meaningful share of tracked competitors (48.30 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-48.8% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cyteir Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cyteir Therapeutics Inc | 25.07 | 25.30 | - |
| Madrigal Pharmaceuticals Inc | 0.72 | 3.52 | 0.60 |
| Hutchmed china Limited | 0.23 | 4.96 | 0.10 |
| Nuvalent Inc | 1.98 | 13.90 | - |
| Immunogen inc | 3.66 | 4.39 | 0.22 |
| Blueprint Medicines Corporation | 0.36 | 3.16 | 2.48 |
Sign in to see all peers for Cyteir Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cyteir Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cyteir Therapeutics Inc | Q3 2023 | - | - |
| Madrigal Pharmaceuticals Inc | Q2 2026 | +71.2 % | - |
| Hutchmed china Limited | Q4 2025 | -13.0 % | +1,099.2 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Immunogen inc | Q3 2023 | +637.7 % | - |
| Blueprint Medicines Corporation | Q1 2025 | +55.5 % | -99.4 % |
| PEERS TOTAL | +19.4 % | - |
Sign in to see all peers for Cyteir Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cyteir Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cyteir Therapeutics Inc | Q3 2023 | - | - |
| Madrigal Pharmaceuticals Inc | Q2 2026 | - | - |
| Hutchmed china Limited | Q4 2025 | -3.6 % | -44.2 % |
| Nuvalent Inc | Q1 2026 | - | - |
| Immunogen inc | Q3 2023 | - | +124.9 % |
| Blueprint Medicines Corporation | Q1 2025 | -12.2 % | +65.9 % |
Sign in to see all peers for Cyteir Therapeutics Inc .
Cyteir Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cyteir Therapeutics Inc | - | - | - |
| Madrigal Pharmaceuticals Inc | - | - | - |
| Hutchmed china Limited | 26.11% | 30.87% | 36.98% |
| Nuvalent Inc | - | - | - |
| Immunogen inc | - | - | - |
| Blueprint Medicines Corporation | - | - | - |
Sign in to see all peers for Cyteir Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cyteir Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cyteir Therapeutics Inc | - | 0.07 |
| Madrigal Pharmaceuticals Inc | - | 11.74 |
| Hutchmed china Limited | 27.17 | 22.49 |
| Nuvalent Inc | - | 2,303.80 |
| Immunogen inc | - | 31.23 |
| Blueprint Medicines Corporation | - | 15.33 |
| PEERS AVERAGE | - | 15.62 |
Sign in to see all peers for Cyteir Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.